Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 604 - 616 |
| Number of pages | 13 |
| Journal | Oncotarget |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2015 |
Cite this
}
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. / Takizawa, Itsuhiro; Lawrence, Mitchell G; Balanathan, Preetika; Rebello, Richard; Pearson, Helen B; Garg, Elika; Pedersen, John S; Pouliot, Normand; Nadon, Robert; Watt, Matthew J; Taylor, Renea A; Humbert, Patrick O; Topisirovic, Ivan; Larsson, Ola; Risbridger, Gail P; Furic, Luc.
In: Oncotarget, Vol. 6, No. 2, 2015, p. 604 - 616.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity
AU - Takizawa, Itsuhiro
AU - Lawrence, Mitchell G
AU - Balanathan, Preetika
AU - Rebello, Richard
AU - Pearson, Helen B
AU - Garg, Elika
AU - Pedersen, John S
AU - Pouliot, Normand
AU - Nadon, Robert
AU - Watt, Matthew J
AU - Taylor, Renea A
AU - Humbert, Patrick O
AU - Topisirovic, Ivan
AU - Larsson, Ola
AU - Risbridger, Gail P
AU - Furic, Luc
PY - 2015
Y1 - 2015
N2 - While high doses of estrogen, in combination with androgens, can initiate prostate cancer (PCa) via activation of the estrogen receptor alpha (ERalpha), the role of ERalpha in PCa cells within established tumors is largely unknown. Here we show that expression of ERalpha is increased in high grade human PCa. Similarly, ERalpha is elevated in mouse models of aggressive PCa driven by MYC overexpression or deletion of PTEN. Within the prostate of PTEN-deficient mice, there is a progressive pattern of ERalpha expression: low in benign glands, moderate in tumors within the dorsal, lateral and ventral lobes, and high in tumors within the anterior prostate. This expression significantly correlates with the proliferation marker Ki67. Furthermore, in vitro knockdown of ERalpha in cells derived from PTEN-deficient tumors causes a significant and sustained decrease in proliferation. Depletion of ERalpha also reduces the activity of the PI3K and MAPK pathways, both downstream targets of non-genomic ERalpha action. Finally, ERalpha knockdown reduces the levels of the MYC protein and lowers the sensitivity of cellular proliferation to glucose withdrawal, which correlates with decreased expression of the glucose transporter GLUT1. Collectively, these results demonstrate that ERalpha orchestrates proliferation and metabolism to promote the neoplastic growth of PCa cells.
AB - While high doses of estrogen, in combination with androgens, can initiate prostate cancer (PCa) via activation of the estrogen receptor alpha (ERalpha), the role of ERalpha in PCa cells within established tumors is largely unknown. Here we show that expression of ERalpha is increased in high grade human PCa. Similarly, ERalpha is elevated in mouse models of aggressive PCa driven by MYC overexpression or deletion of PTEN. Within the prostate of PTEN-deficient mice, there is a progressive pattern of ERalpha expression: low in benign glands, moderate in tumors within the dorsal, lateral and ventral lobes, and high in tumors within the anterior prostate. This expression significantly correlates with the proliferation marker Ki67. Furthermore, in vitro knockdown of ERalpha in cells derived from PTEN-deficient tumors causes a significant and sustained decrease in proliferation. Depletion of ERalpha also reduces the activity of the PI3K and MAPK pathways, both downstream targets of non-genomic ERalpha action. Finally, ERalpha knockdown reduces the levels of the MYC protein and lowers the sensitivity of cellular proliferation to glucose withdrawal, which correlates with decreased expression of the glucose transporter GLUT1. Collectively, these results demonstrate that ERalpha orchestrates proliferation and metabolism to promote the neoplastic growth of PCa cells.
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359242/pdf/oncotarget-06-604.pdf
U2 - 10.18632/oncotarget.2820
DO - 10.18632/oncotarget.2820
M3 - Article
VL - 6
SP - 604
EP - 616
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 2
ER -